FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366992450> ?p ?o ?g. }

• W4366992450 endingPage "399" @default.
• W4366992450 startingPage "387" @default.
• W4366992450 abstract "We launched a prospective phase 2 clinical trial to explore the safety and efficacy of hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC).Patients with newly diagnosed LA-NSCLC with unresectable stage III disease were recruited between June 2018 and June 2020. Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2 and nedaplatin 25 mg/m2). The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), objective response rate (ORR), and toxicities.From June 2018 to June 2020, 75 patients were enrolled with a median follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease progression or death was recorded in 44 (58.7%) patients, with a median PFS of 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1- and 2-year PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), respectively. The median OS, DMFS, and LRFS had not been reached at the time of the last follow-up. The 1- and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 acute pneumonitis occurred during follow-up.Hypo-RT followed by hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory local control and survival outcomes with moderate radiation-induced toxicity in patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened treatment time and provided the potential opportunity for the combination of consolidative immunotherapy." @default.
• W4366992450 created "2023-04-27" @default.
• W4366992450 creator A5007692427 @default.
• W4366992450 creator A5017366969 @default.
• W4366992450 creator A5026316177 @default.
• W4366992450 creator A5033276996 @default.
• W4366992450 creator A5040308577 @default.
• W4366992450 creator A5045238538 @default.
• W4366992450 creator A5052910310 @default.
• W4366992450 creator A5054109175 @default.
• W4366992450 creator A5058762407 @default.
• W4366992450 creator A5059971691 @default.
• W4366992450 creator A5066349538 @default.
• W4366992450 creator A5071672663 @default.
• W4366992450 creator A5085972486 @default.
• W4366992450 creator A5091584882 @default.
• W4366992450 date "2023-10-01" @default.
• W4366992450 modified "2023-10-12" @default.
• W4366992450 title "Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)" @default.
• W4366992450 cites W1002705242 @default.
• W4366992450 cites W1146179709 @default.
• W4366992450 cites W1949312729 @default.
• W4366992450 cites W1968899146 @default.
• W4366992450 cites W1984068275 @default.
• W4366992450 cites W2030816399 @default.
• W4366992450 cites W2032034907 @default.
• W4366992450 cites W2033699280 @default.
• W4366992450 cites W2045313863 @default.
• W4366992450 cites W2048569122 @default.
• W4366992450 cites W2049523263 @default.
• W4366992450 cites W2058344766 @default.
• W4366992450 cites W2115922569 @default.
• W4366992450 cites W2122274531 @default.
• W4366992450 cites W2142595173 @default.
• W4366992450 cites W2145653040 @default.
• W4366992450 cites W2147286476 @default.
• W4366992450 cites W2151415400 @default.
• W4366992450 cites W2152939220 @default.
• W4366992450 cites W2309884927 @default.
• W4366992450 cites W2496326245 @default.
• W4366992450 cites W2549271198 @default.
• W4366992450 cites W2569628438 @default.
• W4366992450 cites W2621243763 @default.
• W4366992450 cites W2753065806 @default.
• W4366992450 cites W2754041892 @default.
• W4366992450 cites W2788945007 @default.
• W4366992450 cites W2807552403 @default.
• W4366992450 cites W2886119834 @default.
• W4366992450 cites W2911260009 @default.
• W4366992450 cites W2944989507 @default.
• W4366992450 cites W2995072671 @default.
• W4366992450 cites W3014909787 @default.
• W4366992450 cites W3015090990 @default.
• W4366992450 cites W3015361910 @default.
• W4366992450 cites W3021058477 @default.
• W4366992450 cites W3094399418 @default.
• W4366992450 cites W3167348704 @default.
• W4366992450 cites W3175711134 @default.
• W4366992450 cites W3179352219 @default.
• W4366992450 cites W4206133183 @default.
• W4366992450 cites W4206916312 @default.
• W4366992450 cites W4210638644 @default.
• W4366992450 cites W4226030374 @default.
• W4366992450 cites W4226175083 @default.
• W4366992450 doi "https://doi.org/10.1016/j.ijrobp.2023.04.021" @default.
• W4366992450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37100160" @default.
• W4366992450 hasPublicationYear "2023" @default.
• W4366992450 type Work @default.
• W4366992450 citedByCount "1" @default.
• W4366992450 crossrefType "journal-article" @default.
• W4366992450 hasAuthorship W4366992450A5007692427 @default.
• W4366992450 hasAuthorship W4366992450A5017366969 @default.
• W4366992450 hasAuthorship W4366992450A5026316177 @default.
• W4366992450 hasAuthorship W4366992450A5033276996 @default.
• W4366992450 hasAuthorship W4366992450A5040308577 @default.
• W4366992450 hasAuthorship W4366992450A5045238538 @default.
• W4366992450 hasAuthorship W4366992450A5052910310 @default.
• W4366992450 hasAuthorship W4366992450A5054109175 @default.
• W4366992450 hasAuthorship W4366992450A5058762407 @default.
• W4366992450 hasAuthorship W4366992450A5059971691 @default.
• W4366992450 hasAuthorship W4366992450A5066349538 @default.
• W4366992450 hasAuthorship W4366992450A5071672663 @default.
• W4366992450 hasAuthorship W4366992450A5085972486 @default.
• W4366992450 hasAuthorship W4366992450A5091584882 @default.
• W4366992450 hasConcept C126322002 @default.
• W4366992450 hasConcept C143998085 @default.
• W4366992450 hasConcept C146357865 @default.
• W4366992450 hasConcept C151730666 @default.
• W4366992450 hasConcept C188816634 @default.
• W4366992450 hasConcept C203092338 @default.
• W4366992450 hasConcept C207103383 @default.
• W4366992450 hasConcept C2776256026 @default.
• W4366992450 hasConcept C2776694085 @default.
• W4366992450 hasConcept C2780739268 @default.
• W4366992450 hasConcept C2781190966 @default.
• W4366992450 hasConcept C31760486 @default.
• W4366992450 hasConcept C44249647 @default.
• W4366992450 hasConcept C509974204 @default.

• next